JUN and renal cell carcinoma: A large number of studies have also shown that these molecules are involved in the regulation of a variety of malignant tumors, such as MUC4 can be used as a new tumor antigen in pancreatic cancer immunotherapy [28], and MUC12 promotes renal cell carcinoma through the c-Jun/TGF-βsignaling pathway [29], MUC1 confers radioresistance in head and neck squamous cell carcinoma cells [30].But the regulatory network between MUC13 and these molecules needs to be further explored.